In people with type 2 diabetes, the drug tirzepatide lowers proinsulin and the ratio of proinsulin to insulin more than dulaglutide, suggesting more efficient insulin production and less stress in...
Mechanism
Synthesis from 1 study
Tirzepatide helps the insulin-making cells in the pancreas work more smoothly by activating two special receptors, which reduces the strain they feel when making insulin. This lets them turn raw insulin into the right form more cleanly, so less faulty insulin leaks out. Other effects, like better...
Most probable mechanism
Tirzepatide activates two specific receptors on insulin-producing cells in the pancreas, which helps these cells work more efficiently and reduces the strain they feel when making insulin. This lets them convert the raw version of insulin into the final, usable form more cleanly, so less faulty insulin is released into the blood.
Tirzepatide binds to both GIP and GLP-1 receptors on pancreatic beta cells
Receptor activation enhances intracellular signaling pathways that increase glucose-dependent insulin secretion and improve protein folding capacity
Improved protein folding reduces accumulation of misfolded proinsulin in the endoplasmic reticulum, lowering endoplasmic reticulum stress
Reduced endoplasmic reticulum stress increases the efficiency of proinsulin conversion to mature insulin, decreasing aberrant proinsulin secretion
Less supported by current evidence, but not ruled out
Tirzepatide triggers fat tissue to release more signaling molecules that help the body use insulin better, which means the pancreas doesn't have to work as hard to lower blood sugar.
Tirzepatide activates GIP receptors on adipocytes
GIP receptor activation increases secretion of adiponectin and IGFBP-1/2 from adipose tissue
Elevated adiponectin and IGFBP-1/2 enhance glucose uptake in muscle and fat and reduce hepatic glucose production
Improved systemic insulin sensitivity reduces the demand on beta cells to secrete insulin, indirectly lowering proinsulin processing burden
Tirzepatide tells the liver to make less sugar, which means the pancreas doesn't need to produce as much insulin to keep blood sugar under control.
Tirzepatide activates GLP-1 and GIP receptors on pancreatic alpha cells
Receptor activation inhibits glucagon secretion from alpha cells
Reduced glucagon signaling decreases hepatic glucose production
Lower hepatic glucose output reduces the demand for insulin secretion, decreasing beta-cell stress and proinsulin processing burden
Evidence from Studies
Supporting (1)
Community contributions welcome
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.